FTC is challenging "roll-up" acquisitions and price-setting agreements with competitors in Texas. The 106-page complaint includes allegations of market-allocation, monopolization, conspiracy to monopolize, and more. It also puts a spotlight on the private equity firm that backed the alleged anticompetitive practices. We'll discuss the theories and challenges raised by this action and what's next.
Sponsored by the Antitrust Law Section's Health Care and Pharmaceuticals and Federal Civil Enforcement Committees.
The content of this program does not meet requirements for continuing legal education (CLE) accreditation. You will not receive CLE credit for participating.
